These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30072125)

  • 1. Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
    Barlas RS; Loke YK; Mamas MA; Bettencourt-Silva JH; Ford I; Clark AB; Bowles KM; Metcalf AK; Potter JF; Myint PK
    Am J Cardiol; 2018 Sep; 122(6):1085-1090. PubMed ID: 30072125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet Therapy After Noncardioembolic Stroke.
    Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
    Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
    Milionis H; Ntaios G; Papavasileiou V; Spengos K; Manios E; Elisaf M; Vemmos K
    J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2769-2777. PubMed ID: 28756905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
    Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
    Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
    Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
    Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    Sacco RL; Diener HC; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; Vandermaelen C; Voigt T; Weber M; Yoon BW;
    N Engl J Med; 2008 Sep; 359(12):1238-51. PubMed ID: 18753638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
    Hills NK; Johnston SC
    Stroke; 2008 Apr; 39(4):1228-32. PubMed ID: 18323509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Paciaroni M; Ince B; Hu B; Jeng JS; Kutluk K; Liu L; Lou M; Parfenov V; Wong KSL; Zamani B; Paek D; Min Han J; Del Aguila M; Girotra S
    Cardiovasc Ther; 2019; 2019():1607181. PubMed ID: 31867054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
    Christiansen CB; Pallisgaard J; Gerds TA; Olesen JB; Jørgensen ME; Numé AK; Carlson N; Kristensen SL; Gislason G; Torp-Pedersen C
    BMC Neurol; 2015 Nov; 15():225. PubMed ID: 26525411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
    Bath PM; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Heptinstall S; James M; Krishnan K; Markus HS; Pocock S; Ranta A; Robinson TG; Flaherty K; Scutt P; Venables GS; Woodhouse LJ; Sprigg N
    Int J Stroke; 2017 Jul; 12(5):524-538. PubMed ID: 27811309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
    Chaturvedi S
    Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
    Tillman H; Johnston SC; Farrant M; Barsan W; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Easton JD
    JAMA Neurol; 2019 Jul; 76(7):774-782. PubMed ID: 31034032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
    Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
    Xu H; Ping Y; Lin H; He P; Li W; Dai H
    Transl Stroke Res; 2017 Jun; 8(3):228-233. PubMed ID: 28039577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke.
    Hilkens NA; Algra A; Kappelle LJ; Bath PM; Csiba L; Rothwell PM; Greving JP;
    Neurology; 2018 Feb; 90(8):e683-e689. PubMed ID: 29374102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG; Parekh A; Ezekowitz MD
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
    Kim D; Park JM; Kang K; Cho YJ; Hong KS; Lee KB; Park TH; Lee SJ; Kim JG; Han MK; Kim BJ; Lee J; Cha JK; Kim DH; Nah HW; Kim DE; Ryu WS; Kim JT; Choi KH; Choi JC; Lee BC; Yu KH; Oh MS; Kim WJ; Kwon JH; Shin DI; Sohn SI; Hong JH; Lee JS; Lee J; Gorelick PB; Bae HJ
    Stroke; 2019 May; 50(5):1184-1192. PubMed ID: 30932785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.